MX2021009687A - Tratamiento de amiloidosis al con la combinacion de anticuerpos monoclonales contra cadenas ligeras de inmunoglobulina y las moleculas de membrana de linfocitos cd38 en celulas inmunitarias productoras de anticuerpos y otras celulas. - Google Patents
Tratamiento de amiloidosis al con la combinacion de anticuerpos monoclonales contra cadenas ligeras de inmunoglobulina y las moleculas de membrana de linfocitos cd38 en celulas inmunitarias productoras de anticuerpos y otras celulas.Info
- Publication number
- MX2021009687A MX2021009687A MX2021009687A MX2021009687A MX2021009687A MX 2021009687 A MX2021009687 A MX 2021009687A MX 2021009687 A MX2021009687 A MX 2021009687A MX 2021009687 A MX2021009687 A MX 2021009687A MX 2021009687 A MX2021009687 A MX 2021009687A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- light chains
- immunoglobulin light
- amyloidosis
- lymphocytes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962804721P | 2019-02-12 | 2019-02-12 | |
| PCT/US2019/066648 WO2020167376A1 (en) | 2019-02-12 | 2019-12-16 | Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009687A true MX2021009687A (es) | 2021-12-10 |
Family
ID=69182616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009687A MX2021009687A (es) | 2019-02-12 | 2019-12-16 | Tratamiento de amiloidosis al con la combinacion de anticuerpos monoclonales contra cadenas ligeras de inmunoglobulina y las moleculas de membrana de linfocitos cd38 en celulas inmunitarias productoras de anticuerpos y otras celulas. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20220213223A1 (https=) |
| EP (1) | EP3923954A1 (https=) |
| JP (2) | JP2022520572A (https=) |
| KR (1) | KR20210143752A (https=) |
| CN (2) | CN119950702A (https=) |
| AU (2) | AU2019429147B2 (https=) |
| BR (1) | BR112021015870A2 (https=) |
| CA (1) | CA3129890A1 (https=) |
| CL (1) | CL2021002140A1 (https=) |
| EA (1) | EA202192235A1 (https=) |
| IL (1) | IL285480A (https=) |
| JO (1) | JOP20210220A1 (https=) |
| MA (1) | MA54923A (https=) |
| MX (1) | MX2021009687A (https=) |
| PH (1) | PH12021551960A1 (https=) |
| SG (1) | SG11202108767PA (https=) |
| WO (1) | WO2020167376A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12021552135A1 (en) | 2019-03-05 | 2022-08-31 | Prothena Biosciences Ltd | Methods of treating al amyloidosis |
| MX2023000949A (es) | 2020-07-23 | 2023-02-22 | Othair Prothena Ltd | Anticuerpos anti-beta-amiloide (abeta). |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| US8263746B2 (en) | 2004-02-06 | 2012-09-11 | Morphosys Ag | Anti-CD38 human antibodies and uses thereof |
| EP2567976B1 (en) | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| DK2237803T3 (en) | 2007-12-28 | 2015-10-05 | Prothena Biosciences Ltd | Treatment and prophylaxis of amyloidosis |
| DK2580243T3 (da) | 2010-06-09 | 2020-01-13 | Genmab As | Antibodies against human cd38 |
| SG10201604104PA (en) | 2011-10-25 | 2016-07-28 | Prothena Therapeutics Ltd | Antibody formulations and methods |
| AU2012328524B2 (en) | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| MX389805B (es) * | 2015-05-20 | 2025-03-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
| DK3827845T3 (da) | 2015-11-03 | 2022-05-23 | Janssen Biotech Inc | Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf |
| WO2018005967A1 (en) * | 2016-06-30 | 2018-01-04 | Prothena Therapeutics Limited | Compositions for treating amyloidosis |
-
2019
- 2019-12-16 AU AU2019429147A patent/AU2019429147B2/en active Active
- 2019-12-16 BR BR112021015870A patent/BR112021015870A2/pt unknown
- 2019-12-16 EA EA202192235A patent/EA202192235A1/ru unknown
- 2019-12-16 JP JP2021547075A patent/JP2022520572A/ja not_active Withdrawn
- 2019-12-16 CN CN202510068246.0A patent/CN119950702A/zh active Pending
- 2019-12-16 EP EP19839484.3A patent/EP3923954A1/en active Pending
- 2019-12-16 PH PH1/2021/551960A patent/PH12021551960A1/en unknown
- 2019-12-16 MX MX2021009687A patent/MX2021009687A/es unknown
- 2019-12-16 MA MA054923A patent/MA54923A/fr unknown
- 2019-12-16 WO PCT/US2019/066648 patent/WO2020167376A1/en not_active Ceased
- 2019-12-16 CN CN201980094744.5A patent/CN113924099A/zh active Pending
- 2019-12-16 US US17/429,876 patent/US20220213223A1/en not_active Abandoned
- 2019-12-16 SG SG11202108767PA patent/SG11202108767PA/en unknown
- 2019-12-16 CA CA3129890A patent/CA3129890A1/en active Pending
- 2019-12-16 KR KR1020217029118A patent/KR20210143752A/ko not_active Ceased
-
2021
- 2021-08-09 IL IL285480A patent/IL285480A/en unknown
- 2021-08-11 JO JOP/2021/0220A patent/JOP20210220A1/ar unknown
- 2021-08-12 CL CL2021002140A patent/CL2021002140A1/es unknown
-
2024
- 2024-10-18 US US18/920,634 patent/US20250075007A1/en active Pending
- 2024-11-12 JP JP2024197437A patent/JP2025015588A/ja active Pending
-
2025
- 2025-02-13 AU AU2025200997A patent/AU2025200997A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MA54923A (fr) | 2021-12-22 |
| JP2022520572A (ja) | 2022-03-31 |
| CN119950702A (zh) | 2025-05-09 |
| BR112021015870A2 (pt) | 2021-11-03 |
| SG11202108767PA (en) | 2021-09-29 |
| IL285480A (en) | 2021-09-30 |
| JP2025015588A (ja) | 2025-01-30 |
| CA3129890A1 (en) | 2020-08-20 |
| CN113924099A (zh) | 2022-01-11 |
| AU2019429147A1 (en) | 2021-09-09 |
| US20220213223A1 (en) | 2022-07-07 |
| EP3923954A1 (en) | 2021-12-22 |
| PH12021551960A1 (en) | 2022-07-18 |
| WO2020167376A8 (en) | 2020-10-29 |
| CL2021002140A1 (es) | 2022-04-18 |
| AU2019429147B2 (en) | 2024-11-14 |
| EA202192235A1 (ru) | 2022-01-19 |
| WO2020167376A1 (en) | 2020-08-20 |
| JOP20210220A1 (ar) | 2023-01-30 |
| AU2025200997A1 (en) | 2025-03-13 |
| KR20210143752A (ko) | 2021-11-29 |
| US20250075007A1 (en) | 2025-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550650A1 (en) | Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof | |
| EA202092945A1 (ru) | Различные антигенсвязывающие домены, новые платформы и другие улучшения для клеточной терапии | |
| ECSP20082648A (es) | Anticuerpos anti-sirpa y métodos de utilización de los mismos | |
| CL2021002140A1 (es) | Tratamiento de amiloidosis al con la combinación de anticuerpos monoclonales contra cadenas ligeras de inmunoglobulina y las moléculas de membrana de linfocitos cd38 en células inmunitarias productoras de anticuerpos y otras células. | |
| CO6251371A2 (es) | Un anticuerpo anti-cd37 derivado de un anticuerpo monoclonal murino | |
| CL2020002613A1 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
| UY37928A (es) | Anticuerpos anti-cd38 y métodos de uso | |
| MA53742A (fr) | Molécules de liaison à l'antigène capables de se lier à cd3 et cd137 mais pas simultanément | |
| JOP20200343A1 (ar) | بروتين ربط مولد ضد مضاد لـ steap1 | |
| EA202190608A1 (ru) | Однодоменные анти-bcma антитела и их применение | |
| MX2021002710A (es) | Anticuerpos anti-c5 humanizados y usos de los mismos. | |
| MX2021015302A (es) | Metodos de purificacion de anticuerpos y composiciones de estos. | |
| MX382703B (es) | ANTICUERPOS IGG MODIFICADOS QUE SE UNEN AL FACTOR DE CRECIMIENTO TRANSFORMANTE-ß1 CON ALTA AFINIDAD, AVIDEZ Y ESPECIFICIDAD. | |
| EA202190954A1 (ru) | Гуманизированное моноклональное антитело против n-укороченного бета-амилоида | |
| MX2020010722A (es) | Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos. | |
| EP4112722C0 (en) | ANTI-VIM CARBAPENEMASE HYBRIDOMA CELL STRAIN, MONOCLONAL ANTIBODY AND APPLICATION | |
| AR102042A1 (es) | ANTICUERPO CONTRA INMUNOGLOBULINAS b (ANTI Igb HUMANA) | |
| AR119496A1 (es) | Proteínas de unión a antígeno anti-il13 | |
| AR115257A1 (es) | Anticuerpos de fijación a bcma y sus usos | |
| JOP20250298A1 (ar) | تركيبات جسم مضاد لإنتيجرين α4β7 وطرق استخدامها | |
| MY210310A (en) | Methods for treatment of subjects with psoriatic arthritis | |
| WO2014145961A3 (en) | Hybridoma clones and monoclonal antibodies to tetraspanin 8 | |
| JP2021517153A5 (ja) | Ｍｏｓｐｄ２およびｔ細胞またはｎｋ細胞特異的分子に対する二重特異性抗体 | |
| HK40067146A (en) | Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells | |
| HK40067140A (en) | Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells |